Global Tigecycline Products Market: Regional Analysis

On the basis of region, the global Tigecycline Products Market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. In North America, the demand for use of tigecycline is increasing due to high prevalence of chlamydia trachomtis. For instance, according to the Centers for Disease Control and Prevention, in 2016, 1,598,354 cases of chlamydia trachomatis infection were reported in the U.S., and 497.3 cases per 100,000 were reported in 2015. Therefore, pharmaceutical companies are focusing on product launches for the treatment of bacterial infectious disease. For instance, in 2016, Fresenius Kabi announced the launch of Tigecycline injection, a generic version of Pfizer’s tygacil with single dose vial in the U.S.

Tigecycline is an antibiotic available under brand name Tygacil which is used to treat serious bacterial infections such as urinary tract infections, acne, gonorrhea, and chlamydia. Tigecycline is used as an alternative agent for the treatment of resistant gram positive and gram negative infection, especially in patients with a history of penicillin allergy or antimicrobial related toxicities. Moreover, tigecycline binds to bacterial ribosomes and prevents bacterial ribosomes from producing cell protein needed for bacterial growth and multiplication but does not kill bacteria. Tigecycline is administrated through intravenous infusion over 30 to 60 minutes and initial dose of tigecycline for bacterial infection treatment is 100 mg followed by 50 mg every 12 hour. Moreover, for complicated skin infection, recommended duration of treatment is 14 to 15 days and 7 to 14 days for treatment of community-acquired bacterial pneumonia.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/tigecycline-products-market-4168

Global Tigecycline Products Market: Drivers

The increasing prevalence of gonorrhea in the U.S. is driving demand for tigecycline products in the market. For instance, according to the Centers for Disease Control and Prevention’s 2017 report, in the U.S, around 555,608 cases of gonorrhea were reported. Therefore, pharmaceutical companies are focusing on launching products for treatment of bacterial infections due to increasing prevalence. For instance, in 2017, Sandoz Inc. launched AP-rated generic version of Tygacil (Tigecycline) injection at a cheaper price compared to branded products in order to increase affordability of the drug. These factors are expected to drive growth of global tigecycline products market.

Global Tigecycline Products Market: COVID-19 Impact Analysis

The COVID-19 pandemic has affected several markets across the globe. Pharmaceutical companies are facing difficulties such as regulatory revisions, changes in demand, delay in generic medicine approvals, disruption in supply chain, and product exportation restriction due to lockdown policies implemented by governments. These factors are negatively affecting the growth of the global tigecycline products market.

Global Tigecycline Products Market: Restraints

Tigecycline antibiotic is characterized by side effects such as lower back or side pain, painful or difficult urination, problems with vision or hearing, cough or hoarseness, fever or chills, and headache. Moreover,the use of tigecycline is restricted due to increase in mortality in hospital-acquired or ventilator-associated pneumonia. Moreover, patients prefer oral tablets (amoxicillin) to injection (tigecycline) for treatment of bacterial infection, due to the cost effectiveness of oral amoxicillin. Cost of 500 mg amoxicillin oral tablet is US$ 23.99, while cost of the tigecycline injection is US$ 79.22. These factors are expected to restrain growth of the global tigecycline products market.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/4168

In Europe, there is major burden of chlamydia and gonorrhea due to increasing prevalence. For instance, according to the National Health Service’s 2018 report, in England, over 44,500 people were diagnosed with gonorrhea in men and women of age under 25 in 2017. Therefore, pharmaceutical companies are focusing on launching product for treatment of bacterial infectious diseases. For instance, in February 2020, European Medicines Agency approved marketing authorization of tigecycline injection by Accord Healthcare for treatment of bacterial skin diseases. These factors are expected to drive growth of the global tigecycline products market during the forecast period.

Global Tigecycline Products Market: Key Players

Key players operating in the global tigecycline products market are Amneal Pharmaceuticals, Inc., Novartis International AG, Xellia pharmaceuticals ApS, Accord Healthcare Inc., Apotex, Inc., Aurobindo Pharma Limited, Fresenius Kabi USA LLC, Pfizer Inc., Abbott Laboratories, and AstraZeneca plc.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/4168

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737